NEW ORLEANS, Louisiana — An experimental new drug for glaucoma and ocular hypertension is as effective as latanoprost but causes different adverse events, the results of a phase 3 clinical trial ...
Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with ...
Fort Lauderdale, Florida (May 8, 2002) – Switching to XALATAN® (latanoprost ophthalmic solution) once daily from monotherapy with other medications, including prostaglandin derivatives, for open angle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback